Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
9
×
life sciences
national blog main
national top stories
9
×
san francisco top stories
boston blog main
boston top stories
san francisco blog main
national
new york blog main
new york top stories
cancer
clinical trials
novartis
san diego blog main
san diego top stories
texas blog main
texas top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
roche
seattle blog main
seattle top stories
wisconsin blog main
wisconsin top stories
amgen
biogen
boston
deals
gene therapy
medicare
merck
pfizer
What
patients
9
×
medicine
drug
bio
fda
market
roundup
cancer
friday
new
therapy
acquisitions
advantages
ago
albert
allison
alnylam
analytics
approve
approved
atrophy
awaits
bar
becker
benefiting
biggest
billions
biofourmis
biological
boston
bourla
brings
cancers
ceo
coming
company
countless
crispr
crossed
daily
Language
unset
unknown
Current search:
biotech
×
patients
×
" national top stories "
×
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September
@xconomy.com
5 years ago
Nobel Medicine Prize Honors Cancer Immunotherapy Pioneers Allison & Honjo
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision